NCT06287086View on ClinicalTrials.gov

Clinical Study on the Safety and Efficacy of BRL-101 in the Treatment of Sickle Cell Disease

NANot yet recruitingINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

June 14, 2024

Primary Completion Date

August 20, 2025

Study Completion Date

June 10, 2026

Conditions
Sickle Cell Disease
Interventions
DRUG

BRL-101 autologous hematopoietic stem and progenitor cells injection

CD34 + autologous hematopoietic stem and progenitor cells edited at the BCL11A gene.

Sponsors
All Listed Sponsors
collaborator

Institute of Hematology & Hospital of Blood Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College

UNKNOWN

lead

Bioray Laboratories

INDUSTRY

NCT06287086 - Clinical Study on the Safety and Efficacy of BRL-101 in the Treatment of Sickle Cell Disease | Biotech Hunter | Biotech Hunter